EP Patent

EP3461488A1 — Combination of a dbait molecule and a hdac inhibitor for treating cancer

Assigned to Valerio Therapeutics SA · Expires 2019-04-03 · 7y expired

What this patent protects

The present invention relates to the combination of a Dbait acid molecule with a HDAC inhibitor for treating cancer.

USPTO Abstract

The present invention relates to the combination of a Dbait acid molecule with a HDAC inhibitor for treating cancer.

Drugs covered by this patent

Beleodaq (belinostat) · Acrotech Biopharma

Patent Metadata

Patent number: EP3461488A1
Jurisdiction: EP
Classification: —
Expires: 2019-04-03
Drug substance claim: No
Drug product claim: No
Assignee: Valerio Therapeutics SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.